2023

• Noori, N., Edwards, L., Anpalagan, A., Athavale, R., Burling, M., Herbst, U., Brand, A., Kapurubandara, S. (2023). Bilateral salpingectomy as an option of permanent contraception at time of caesarean section: A survey of practice. Australian and New Zealand Journal of Obstetrics and Gynaecology. [More Information]
• Kang, E., Weir, A., Meagher, N., Farrington, K., Nelson, G., Ghatage, P., Lee, C., Riggan, M., Bolithon, A., Popovic, G., Boros, J., Brand, A., et al (2023). CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. Cancer, 129.0(5), 697-713. [More Information]
• Boo, M., Simcock, B., Sykes, P., Brand, A. (2023). Direct oral anticoagulants (DOACs) use for prolonged venous thromboembolism prophylaxis following surgery for gynaecological malignancies in Australia and New Zealand - A clinician survey. Australian and New Zealand Journal of Obstetrics and Gynaecology. [More Information]
• Hayes, S., Obermair, A., Mileshkin, L., Davis, A., Gordon, L., Eakin, E., Janda, M., Beesley, V., Barnes, E., Spence, R., Andrews, J., Brand, A., Lee, C., Stockler, M., et al (2023). Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial. BMJ Open, 13(4), e067925. [More Information]
• Srinivasa, S., Bowman, M., Titterton, L., Harnett, P., Brand, A., Kirk, J., Ragunathan, A. (2023). Mainstream genetic testing for high-grade ovarian, tubal and peritoneal cancers: A tertiary referral centre experience. Australian and New Zealand Journal of Obstetrics and Gynaecology, 63(2), 241-246. [More Information]
• Pitiyarachchi, O., Lee, Y., Sim, H., Srirangan, S., Mapagu, C., Kirk, J., Harnett, P., Balleine, R., Bowtell, D., Samimi, G., Brand, A., Marsh, D., Beale, P., Anderson, L., Bouantoun, N., Provan, P., deFazio, A., et al (2023). Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma. Translational Oncology, 31. [More Information]
• Kobel, M., Kang, E., Weir, A., Rambou, P., Lee, C., Boros, J., Brand, A., Harnett, P., Kennedy, C., deFazio, A., et al (2023). p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. The Journal of Pathology: Clinical Research, 9(3), 208-222. [More Information]
• Yap, S., Vassallo, A., Goldsbury, D., O'Connell, D., Brand, A., Emery, J., deFazio, A., Canfell, K., Steinberg, J. (2023). Pathways to diagnosis of endometrial and ovarian cancer in the 45 and Up Study cohort. Cancer Causes and Control, 34(1), 47-58. [More Information]
• Subramanian, H., Fuchsova, V., Elder, E., Brand, A., Howle, J., deFazio, A., Mann, G., Amis, T., Kairaitis, K. (2023). Screening for obstructive sleep apnoea in post-treatment cancer patients. Cancer Reports, 6(3). [More Information]
• Foster, L., Girgis, C., Kirby, A., Harnett, P., Brand, A. (2023). The use of intraperitoneal chemotherapy for advanced ovarian cancer - The experience of a tertiary referral centre. Australian and New Zealand Journal of Obstetrics and Gynaecology. [More Information]

2022

• Kairaitis, K., Madut, A., Subramanian, H., Trivedi, R., Man, H., Mather, M., Brand, A., Elder, E., Howle, J., Mann, G., Amis, T., deFazio, A. (2022). Cancer sleep symptom-related phenotypic clustering differs across three cancer specific patient cohorts. Journal of Sleep Research. [More Information]
• Cunningham, J., Winham, S., Wang, C., Weiglt, B., Fu, Z., Armasu, S., McCauley, B., Brand, A., Chiew, Y., Elishaev, E., deFazio, A., et al (2022). DNAMethylation Profiles of Ovarian Clear Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 31(1), 132-141. [More Information]
• Cohen, P., Webb, P., King, M., Obermair, A., Gebski, V., Butow, P., Morton, R., Lawson, W., Yates, P., Campbell, R., Brand, A., et al (2022). Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer. International Journal of Gynecological Cancer, 32(4), 560-565. [More Information]
• Weir, A., Kang, E., Meagher, N., Nelson, G., Ghatage, P., Lee, C., Riggan, M., Gentry-Maharaj, A., Ryan, A., Singh, N., Brand, A., Boros, J., Hartnett, P., Kennedy, C., deFazio, A., et al (2022). Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study. British Journal of Cancer, 128(1), 137-147. [More Information]
• Bolton, K., Chen, D., de la Fuente, R., Fu, Z., Murali, R., Köbel, M., Tazi, Y., Cunningham, J., Chan, I., Wiley, B., Brand, A., deFazio, A., et al (2022). Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. Clinical Cancer Research, 28(22), 4947-4956. [More Information]
• Garsed, D., Pandey, A., Fereday, S., Kennedy, C., Takahashi, K., Alsop, K., Hamilton, P., Hendley, J., Chiew, Y., Traficante, N., Provan, P., Brand, A., Harnett, P., et al (2022). The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nature Genetics, 54(12), 1853-1864. [More Information]
• Foster, L., Burling, M., Brand, A. (2022). The utilisation of sentinel lymph node biopsy for endometrial cancer in Australia and New Zealand. Australian and New Zealand Journal of Obstetrics and Gynaecology, 62(1), 104-109. [More Information]
• Heinze, K., Nazeran, T., Lee, S., Krämer, P., Cairns, E., Chiu, D., Leung, S., Kang, E., Meagher, N., Kennedy, C., Boros, J., Sharma, R., Brand, A., George, J., et al (2022). Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. Journal of Pathology, 256(4), 388-401. [More Information]

2021

• Glubb, D., Thompson, D., Aben, K., Alsulimani, A., Amant, F., Annibali, D., Attia, J., Barricarte, A., Beckmann, M., Berchuck, A., deFazio, A., Gao, B., Brand, A., et al (2021). Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 30(1), 217-228. [More Information]
• Madut, A., Fuchsova, V., Man, H., Askar, S., Trivedi, R., Elder, E., Clarke, C., Wain, G., Brand, A., deFazio, A., Amis, T., Kairaitis, K. (2021). Increased prevalence of obstructive sleep apnea in women diagnosed with endometrial or breast cancer. PloS One, 16(4), e0249658-1-e0249658-16. [More Information]
• Trivedi, R., Man, H., Madut, A., Mather, M., Elder, E., Dhillon, H., Brand, A., Howle, J., Mann, G., deFazio, A., Amis, T., Phillips, A., Kairaitis, K., et al (2021). Irregular Sleep/Wake Patterns Are Associated With Reduced Quality of Life in Post-treatment Cancer Patients: A Study Across Three Cancer Cohorts. Frontiers in Neuroscience, 15, 700923. [More Information]
• Foster, L., Brand, A. (2021). Ovarian cancer Old problems, new developments. Medicine Today, 22(6), 51-54.
• Thangavel, D., Gerges, B., Brand, A. (2021). Prospective study of patient satisfaction with enhanced recovery after surgery (ERAS) protocol in the immediate post-operative period in gynaecological oncology. Australian and New Zealand Journal of Obstetrics and Gynaecology, 61(4), 591-598. [More Information]
• Hickey, M., Moss, K., Brand, A., Wrede, C., Domchek, S., Meiser, B., Mishra, G., Joffe, H. (2021). What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecologic Oncology, 161(2), 527-534. [More Information]
• Hickey, M., Moss, K., Krejany, E., Wrede, C., Domchek, S., Kirk, J., Brand, A., Trainer, A., Mishra, G., Baker, F. (2021). What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy. Gynecologic Oncology, 162(2), 447-453. [More Information]
• Hickey, M., Moss, K., Krejany, E., Wrede, C., Brand, A., Kirk, J., Symecko, H., Domchek, S., Tejada-Berges, T., Trainer, A., et al (2021). What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12?months after premenopausal risk-reducing salpingo-oophorectomy. Gynecologic Oncology, 163(1), 148-154. [More Information]

2020

• Schofield, P., Gough, K., Pascoe, M., Bergin, R., White, K., Mileshkin, L., Bernshaw, D., Kinnane, N., Jackson, M., Do, V., Juraskova, I., et al (2020). A nurse- and peer-led psycho-educational intervention to support women with gynaecological cancers receiving curative radiotherapy: The PeNTAGOn randomised controlled trial – ANZGOG 1102. Gynecologic Oncology, 159(3), 785-793. [More Information]
• Heriot, N., Brand, A., Cohen, P., Hegarty, S., Hyde, S., Leung, Y., Zalcberg, J., Rome, R. (2020). Developing an Australian multi-module clinical quality registry for gynaecological cancers: A protocol paper. BMJ Open, 10(2), e034579. [More Information]
• Talhouk, A., George, J., Wang, C., Budden, T., Tan, T., Chiu, D., Kommoss, S., Leong, H., Chen, S., Intermaggio, M., Chiew, Y., Sharma, R., Nevins, N., deFazio, A., et al (2020). Development and validation of the gene expression predictor of high-grade serous ovarian carcinoma molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 26(20), 5411-5423. [More Information]
• Cohen, P., Leung, Y., Anderson, L., Van Der Griend, R., Chivers, P., Bilic, S., Bittinger, S., Brand, A., Bulsara, M., Codde, J., Stockler, M., et al (2020). Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy. Gynecologic Oncology, 159(3), 623-629. [More Information]
• Annett, S., Moore, G., Short, A., Marshall, A., McCrudden, C., Yakkundi, A., Das, S., McCluggage, W., Nelson, L., Harley, I., deFazio, A., Brand, A., Sharma, R., et al (2020). FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. British Journal of Cancer, 122(3), 361-371. [More Information]
• Vermorken, J., van Dam, P., Brand, A. (2020). HIPEC in advanced epithelial ovarian cancer: why is there controversy? Current Opinion in Oncology, 32(5), 451-458. [More Information]
• Millstein, J., Budden, T., Goode, E., Anglesio, M., Talhouk, A., Intermaggio, M., Leong, H., Chen, S., Elatre, W., Gilks, B., Kennedy, C., Sharma, R., Harnett, P., Gao, B., Boros, J., deFazio, A., et al (2020). Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 31(9), 1240-1250. [More Information]

2019

• Sykes, P., Eva, L., Van Der Griend, R., McNally, O., Blomfield, P., Brand, A., Tristram, A., Bergzoll, C., Petrich, S., Kenwright, D., et al (2019). Pathological process has a crucial role in sentinel node biopsy for vulvar cancer. Gynecologic Oncology, 153(2), 292-296. [More Information]
• Velentzis, L., Smith, M., Simms, K., Lew, J., Hall, M., Hughes, S., Yuill, S., Killen, J., Keane, A., Butler, K., Skinner, R., Brand, A., Bateson, D., Armstrong, B., Canfell, K., et al (2019). Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. Gynecologic Oncology, 152(3), 465-471. [More Information]
• Cheasley, D., Wakefield, M., Ryland, G., Allan, P., Alsop, K., Amarasinghe, K., Ananda, S., Anglesio, M., Au-Yeung, G., Bohm, M., Brand, A., Chiew, Y., deFazio, A., Kennedy, C., Sharma, R., et al (2019). The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications, 10(1), 1-11. [More Information]

2018

• Garsed, D., Alsop, K., Fereday, S., Emmanuel, C., Kennedy, C., Etemadmoghadam, D., Gao, B., Gebski, V., Gares, V., Christie, E., Sharma, R., Brand, A., Harnett, P., deFazio, A., et al (2018). Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 24(3), 569-580. [More Information]
• Farrell, R., Liauw, W., Brand, A. (2018). Ovarian Cancer Surgery in Australia and New Zealand: A Survey to Determine Changes in Surgical Practice Over 10 Years. International Journal of Gynecological Cancer, 28(5), 945-950. [More Information]
• Jamieson, A., Brand, A. (2018). Response to: Cervical cancer in women under 25 years of age in Queensland, Australia: To what extent is the diagnosis made by screening cytology? Australian and New Zealand Journal of Obstetrics and Gynaecology, 58(3), E5-E6. [More Information]
• Johnatty, S., Stewart, C., Smith, D., Buchanan, D., Leung, Y., Oehler, M., Brand, A., Webb, P., Spurdle, A. (2018). Risk and prognostic factors for endometrial carcinoma after diagnosis of breast or Lynch-associated cancers - A population-based analysis. Cancer Medicine, 7(12), 6411-6422. [More Information]
• Nagle, C., Crosbie, E., Brand, A., Obermair, A., Oehler, M., Quinn, M., Leung, Y., Spurdle, A., Webb, P. (2018). The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer. Gynecologic Oncology, 150(1), 99-105. [More Information]
• Murali, R., Ring, B., Soslow, R., deFazio, A., Kennedy, C., Brand, A., Harnett, P., Sharma, R., Samimi, G. (2018). TLE3 expression is associated with favorable outcomes in taxane-treated patients with non-serous ovarian carcinoma: A multi-institution study. Gynecologic Oncology, 149, 182-182. [More Information]
• Ring, B., Murali, R., Soslow, R., Bowtell, D., Fereday, S., deFazio, A., Traficante, N., Kennedy, C., Brand, A., Sharma, R., Harnett, P., et al (2018). Transducin-Like enhancer of split 3 (TLE3) expression is associated with taxane sensitivity in nonserous ovarian carcinoma in a three-Cohort study. Cancer Epidemiology Biomarkers and Prevention, 27(6), 680-688. [More Information]

2017

• Brand, A., DiSilvestro, P., Sehouli, J., Berek, J. (2017). Cytoreductive surgery for ovarian cancer: quality assessment. Annals of Oncology, 28(Suppl 8), viii25-viii29. [More Information]
• Janda, M., Gebski, V., Davies, L., Forder, P., Brand, A., Hogg, R., Jobling, T., Land, R., Manolitsas, T., Nascimento, M., et al (2017). Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage i endometrial cancer: A randomized clinical trial. JAMA - Journal of the American Medical Association, 317(12), 1224-1233. [More Information]
• Lindemann, K., Kok, P., Stockler, M., Jaaback, K., Brand, A. (2017). Enhanced recovery after surgery for advanced ovarian cancer: A systematic review of interventions trialed. International Journal of Gynecological Cancer, 27(6), 1274-1282. [More Information]
• Lindemann, K., Kok, P., Stockler, M., Sykes, P., Brand, A. (2017). Enhanced recovery after surgery for suspected ovarian malignancy: A survey of perioperative practice among gynecologic oncologists in Australia and New Zealand to Inform a Clinical Trial. International Journal of Gynecological Cancer, 27(5), 1046-1050. [More Information]
• Cohen, P., Brand, A., Sykes, P., Wrede, D., McNally, O., Eva, L., Rao, A., Campion, M., Stockler, M., Powell, A., et al (2017). Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. BMJ Open, 7(8), 1-9. [More Information]
• Johnatty, S., Tan, Y., Buchanan, D., Bowman, M., Walters, R., Obermair, A., Quinn, M., Blomfield, P., Brand, A., Leung, Y., Kirk, J., et al (2017). Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecologic Oncology, 147(2), 381-387. [More Information]
• McGee, J., Bookman, M., Harter, P., Marth, C., McNeish, I., Moore, K., Poveda, A., Hilpert, F., Hasegawa, K., Brand, A., et al (2017). Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Annals of Oncology, 28(4), 702-710. [More Information]
• Morris, L., Do, V., Chard, J., Brand, A. (2017). Radiation-induced vaginal stenosis: current perspectives. International Journal of Women's Health, 9, 273-279. [More Information]

2016

• Anuradha, S., Donovan, P., Webb, P., Brand, A., Goh, J., Friedlander, M., Oehler, M., Quinn, M., Steer, C., Jordan, S. (2016). Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study. Acta Oncologica, 55(2), 226-233. [More Information]

2015

• Brand, A., Harrison, A., Kumar, K. (2015). "It was definitely very different": An evaluation of palliative care teaching to medical students using a mixed methods approach. Journal of Palliative Care, 31(1), 21-28. [More Information]
• Webb, P., deFazio, A., Protani, M., Ibiebele, T., Nagle, C., Brand, A., Blomfield, P., Grant, P., Perrin, L., Neale, R. (2015). Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. American Journal of Clinical Nutrition, 102(1), 109-114. [More Information]
• Beesley, V., Rowlands, I., Hayes, S., Janda, M., O'Rourke, P., Marquart, L., Quinn, M., Spurdle, A., Obermair, A., Brand, A., et al (2015). Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. Gynecologic Oncology, 136(1), 87-93. [More Information]
• Brand, A. (2015). Jack of all trades, master of none? the need for centralisation of services for rarely performed procedures. Australian and New Zealand Journal of Obstetrics and Gynaecology, 55(3), 298-298. [More Information]
• Kapurubandara, S., Qin, V., Gurram, D., Anpalagan, A., Merkur, H., Hogg, R., Brand, A. (2015). Opportunistic bilateral salpingectomy during gynaecological surgery for benign disease: A survey of current Australian practice. Australian and New Zealand Journal of Obstetrics and Gynaecology, 55(6), 606-611. [More Information]

2014

• Emmanuel, C., Chiew, Y., George, J., Etemadmoghadam, D., Anglesio, M., Sharma, R., Russell, P., Kennedy, C., Fereday, S., Hung, J., Hogg, R., Wain, G., Brand, A., Balleine, R., Clarke, C., Harnett, P., deFazio, A., et al (2014). Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Clinical Cancer Research, 20(24), 6618-6630. [More Information]
• Rowlands, I., Beesley, V., Janda, M., Hayes, S., Obermair, A., Quinn, M., Brand, A., Leung, Y., McQuire, L., Webb, P. (2014). Quality of life of women with lower limb swelling or lymphedema 3-5years following endometrial cancer. Gynecologic Oncology, 133(2), 314-318. [More Information]
• Anuradha, S., Webb, P., Blomfield, P., Brand, A., Friedlander, M., Leung, Y., Obermair, A., Oehler, M., Quinn, M., Steer, C., et al (2014). Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. Medical Journal of Australia, 201(5), 283-288. [More Information]

2013

• Brand, A., King, M. (2013). Does Extensive Upper Abdomen Surgery During Primary Cytoreduction Impact on Long-term Quality of Life? Baseline Plus Longitudinal Quality-of-Life Assessment Would Have Provided a Better Answer. International Journal of Gynecological Cancer, 23(6), 980-981. [More Information]
• Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Bloomfield, P., Grant, P., Kichenadasse, G., Vaughan, M., Brand, A., Shannon, C., Gebski, V., Stockler, M., et al (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4), 359-366. [More Information]

2012

• Brand, A., Do, V., Stenlake, A. (2012). Can an Educational Intervention Improve Compliance With Vaginal Dilator Use in Patients Treated With Radiation for a Gynecological Malignancy? International Journal of Gynecological Cancer, 22(5), 897-904. [More Information]
• Sidhu, V., Lancaster, L., Elliott, D., Brand, A. (2012). Implementation and audit of 'Fast-Track Surgery' in gynaecological oncology surgery. Australian and New Zealand Journal of Obstetrics and Gynaecology, 52(4), 371-376. [More Information]
• Obermair, A., Janda, M., Baker, J., Kondalsamy-Chennakesavan, S., Brand, A., Hogg, R., Jobling, T., Land, R., Manolitsas, T., Nascimento, M., Gebski, V., et al (2012). Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. European Journal of Cancer, 48(8), 1147-1153. [More Information]
• Kondalsamy-Chennakesavan, S., Janda, M., Gebski, V., Baker, J., Brand, A., Hogg, R., Jobling, T., Land, R., Manolitsas, T., Nascimento, M., et al (2012). Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. European Journal of Cancer, 48(14), 2155-2162. [More Information]

2011

• Emmanuel, C., Gava, N., Kennedy, C., Balleine, R., Sharma, R., Wain, G., Brand, A., Hogg, R., Etemadmoghadam, D., George, J., Clarke, C., Harnett, P., deFazio, A., et al (2011). Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PloS One, 6(3), e17617-1-e17617-18. [More Information]
• Brand, A. (2011). Ovarian Cancer Debulking Surgery: A Survey of Practice in Australia and New Zealand. International Journal of Gynecological Cancer, 21(2), 230-235. [More Information]
• Brand, A. (2011). The RANZCOG College Statement on prophylactic oophorectomy in older women undergoing hysterectomy for benign disease: Is the evidence sufficient to change practice? Australian and New Zealand Journal of Obstetrics and Gynaecology, 51(4), 296-300. [More Information]

2010

• Janda, M., Gebski, V., Brand, A., Hogg, R., Jobling, T., Land, R., Manolitsas, T., McCartney, A., Nascimento, M., Neesham, D., Pather, S., et al (2010). Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. The Lancet Oncology, 11(8), 772-780. [More Information]

2009

• Bunting, M., Chan, W., Brand, A., Blomfield, P. (2009). Intraperitoneal chemotherapy for advanced epithelial ovarian malignancy: Lessons learned. Australian and New Zealand Journal of Obstetrics and Gynaecology, 49(6), 667-671. [More Information]
• Wang, W., Do, V., Hogg, R., Wain, G., Brand, A., Bull, C., Stenlake, A., Gebski, V. (2009). Uterine papillary serous carcinoma: patterns of failure and survival. Australian and New Zealand Journal of Obstetrics and Gynaecology, 49(4), 419-425. [More Information]

2008

• Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 14(21), 6924-6932. [More Information]

2007

• Brand, A. (2007). The woman with postmenopausal bleeding. Australian Family Physician, 36(3), 116-120. [More Information]

2006

• Hodgkinson, K., Butow, P., Fuchs, A., Hunt, G., Stenlake, A., Hobbs, K., Brand, A., Wain, G. (2006). Long-term survival from gynecologic cancer: Psychosocial outcomes, supportive care needs and positive outcomes. Gynecologic Oncology, 104(2), 381-389. [More Information]
• Brand, A., Bull, C., Cakir, B. (2006). Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix. International Journal of Gynecological Cancer, 16(1), 288-293. [More Information]